VANCOUVER--(BUSINESS WIRE)--Medifocus, Inc. (TSXV:MFS) is pleased to announce that it has filed a comprehensive response to its IDE application with the FDA in the United States to obtain clearance to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA 1000 System for the treatment of breast cancer in the USA and worldwide. This response was the result of a letter received from the FDA dated July 13, 2009 requesting clarification, recommendations and additional information from Medifocus.
